alexa Adrenoleukodystrophy | UK| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Adrenoleukodystrophy

    Adrenoleukodystrophy (ALD) refers to several different inherited conditions that affect the nervous system and adrenal glands. Other names for it are adrenomyeloneuropathy, childhood cerebral ALD, and Schilder-Addison Complex. The gene that causes ALD was identified in 1993. It occurs in about 1 in 20,000 people and mainly affects men. Women can carry ALD without having any symptoms. The symptoms, treatments, and prognosis of ALD vary depending on which type is present. ALD is not curable, but the progression can be slowed in some cases.

  • Adrenoleukodystrophy

    The genetic bases for all different phenotypic variants of X-ALD are mutations in the gene encoding the peroxisomal ATP-binding cassette (ABC) transporter, ABCD1 (formerly adrenoleukodystrophy protein, ALDP). ABCD1 transports CoA-activated very long-chain fatty acids from the cytosol into the peroxisome for degradation. The phenotypic variability is remarkable ranging from cerebral inflammatory demyelination of childhood onset, leading to death within a few years, to adults remaining pre-symptomatic through more than five decades. There is no general genotype-phenotype correlation in X-ALD.Treatment methods depend on the type of ALD. Steroids can be used to treat Addison’s disease. switching to a diet that contains low levels of VLCFAs, taking Lorenzo’s oil to help lower elevated VLCFA levels, medications to relieve symptoms such as seizures, physical therapy to loosen muscles and reduce spasms

  • Adrenoleukodystrophy

    The minimum incidence of affected males in the United States is estimated to be 1 per 21,000 males, and the combined incidence of affected males and heterozygous women in the total USA population 1:16,800. Somewhat higher figures have been obtained in France, with the most recent estimate of affected males set at 1:15,000 males. Kondrashov estimated that the mutation rate of ABCD1 is 2.64 times 10-8. X-ALD has been observed in all ethnic groups, without evidence of differential rates (Kondrashov 2003). Only 1.7% of affected males have been found to have new mutations. An extended family screening led to the identification of 594 additional affected males, 250 of them asymptomatic, at a time when therapy has the greatest chance of being beneficial, and 1,270 heterozygotes.


High Impact List of Articles

Conference Proceedings